The Centers for Disease Control and Prevention have recommended infants under eight months old get vaccinated for respiratory syncytial virus (RSV) starting in the fall. The disease is currently the "leading cause of hospitalization among infants in the U.S." Yearly, 58,000 to 80,000 children under 5 years of age, most of whom are infants, are hospitalized because of RSV. Some 100 to 300 children die from the disease every year.
The new vaccine, called nirsevimab, was approved in July. It is an antibody vaccine, which varies from typical vaccines. Regular vaccines "train the body's own immune defenses against the virus," while an antibody vaccine "works to directly fend off the virus in the body," CBS News reported. "This new RSV immunization provides parents with a powerful tool to protect their children against the threat of RSV," said CDC director Mandy Cohen. "RSV is the leading cause of hospitalizations for infants and older babies at higher risk and today we have taken an important step to make this life saving product available."
Almost all children will contract RSV by their second birthday, and the risk spikes every year in the winter and early spring months. The virus causes flu-like symptoms including fever, cough and runny nose. In children under three, "the illness may move into the lungs and cause coughing and wheezing," and in some cases "the infection turns to a severe respiratory disease," according to Cedars-Sinai. "I think that we will look back on this, in a short period of time, and see what a major impact this vote has had on the health and wellbeing of children," Dr. José Romero, director of the National Center for Immunization and Respiratory Diseases, said in a meeting for the CDC's Advisory Committee on Immunization Practices, which endorsed giving the vaccine.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
-
Ben Fountain's 6 favorite books about HaitiFeature The award-winning author recommends works by Marie Vieux-Chauvet, Katherine Dunham and more
-
6 picturesque homes in apartments abroad
Feature Featuring a wall of windows in Costa Rica and a luxury department store-turned-home in New Zealand
-
Why 2023 has been the year of strikes and labor movements
The Explainer From Hollywood to auto factories, workers are taking to the picket lines
-
Popular weight loss drugs linked to higher risk of serious gastrointestinal problems
Speed Reads Researchers found that semaglutide, the active ingredient in Wegovy and Ozempic, had a higher risk for side effects like stomach paralysis.
-
What is a 'feminist approach' to cancer care?
The Explainer 800,000 women die from 'preventable' cancers each year due to 'patriarchy', landmark study finds
-
Animals and plants that have been used to fight disease
The Explainer The world's flora and fauna have long been medically important
-
Heat harms the brain more than we think
Warmer temperatures could be affecting us mentally
-
FDA to re-evaluate effectiveness of common nasal congestion ingredient
Speed Read
-
A flesh-eating bacteria is growing in numbers due to climate change
Speed Read
-
Will Medicare drug price controls save lives?
Talking Point Medicare starts negotiating lower drug prices over Big Pharma protests
-
U.S. health agency advises easing federal marijuana restrictions
Speed Read
